Willner & Heller LLC Sells 1,840 Shares of Edwards Lifesciences Co. (NYSE:EW)

Willner & Heller LLC trimmed its stake in Edwards Lifesciences Co. (NYSE:EW) by 30.4% during the 4th quarter, HoldingsChannel reports. The fund owned 4,210 shares of the medical research company’s stock after selling 1,840 shares during the quarter. Willner & Heller LLC’s holdings in Edwards Lifesciences were worth $312,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of EW. Harbor Capital Advisors Inc. raised its stake in shares of Edwards Lifesciences by 2.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after purchasing an additional 273 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after purchasing an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its position in Edwards Lifesciences by 6.7% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Edwards Lifesciences by 9.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock worth $31,571,000 after purchasing an additional 40,348 shares during the last quarter. Finally, AIA Group Ltd raised its stake in Edwards Lifesciences by 91.7% during the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock valued at $49,461,000 after buying an additional 358,556 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. The trade was a 9.73 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,000 shares of company stock valued at $2,195,180. 1.27% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $69.77 on Monday. The stock has a 50 day moving average price of $72.06 and a 200-day moving average price of $71.32. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The stock has a market cap of $41.15 billion, a price-to-earnings ratio of 10.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the firm posted $0.59 earnings per share. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. Equities analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Analyst Upgrades and Downgrades

EW has been the topic of several research reports. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. The Goldman Sachs Group upped their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Finally, Evercore ISI cut their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.